Canada on Track as First G7 Nation to Federally Legalize Cannabis
Vancouver, British Columbia, June 20, 2018 (GLOBE NEWSWIRE) -- EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: AXHLF) (the “Company”) is pleased to raise its hand in support of the Canadian’s Senate approval of the legalization of adult recreational cannabis use, which could occur within eight to twelve weeks.
“The Senate overwhelmingly voted in favour of the revised bill from the House of Commons which should create a fully federally legal cannabis program for Canada within eight to twelve weeks”.” Said Evitrade CEO CK Cheung. “This vote will provide a framework from which companies like ours can utilize advanced scientific research and developments to operate successfully within the cannabis market in Canada.”
The Company recently signed a definitive agreement with Cantech Molecular Research Inc. whose focus is on the development of haploid breeding protocols for plants that will enable the delivery of consistent and predictable biologics each and every growth cycle. A technology that is a solid fit in the recreational, medicinal and pharmaceutical cannabis world.
Management continues to strive to seek optimal business and commercialization strategies for the Company, This, with the continuing engagement of Haywood Securities has the Company planning forward for a bright future.
Contact: C.K. Cheung, CEO
EVITRADE Health Systems Corporation
(formerly Auxellence Health Corporation)
Email info@evahealthsystems.com
Website http://www.evahealthsystems.com
CSE Micro-site: http://thecse.com/en/listings/technology/evitrade-health-systems-corp
US OTC Markets: http://www.otcmarkets.com/stock/AXHLF/news
About EVITRADE Health (CSE: EVA, OTCQB: AXHLF)
EVITRADE (formerly Auxellence Health Corp.), was founded in 2013 to provide online “digital healthcare” services for resolving common health problems. The current markets are weight-management, high blood pressure, high blood glucose and heart arrhythmia.
Disclaimers – Forward Looking Statements
This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, http://thecse.com/en/listings/technology/evitrade-health-systems-corp, and http://www.otcmarkets.com/stock/AXHLF/filings. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.
© 2018 GlobeNewswire, Inc. All Rights Reserved.
Regeneron Pharmaceuticals' (Nasdaq: REGN) REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization
